top of page

Contact

For all general inquiries, please call or send us a message via the form below. We appreciate your interest in SpyGlass Pharma™ and invite you to follow us on LinkedIn for future company updates.

Get in touch

Phone

949-284-6904

Follow us on LinkedIn

  • LinkedIn
Your email has been successfully sent. Thank you for submitting!
texture_bg.jpg

SpyGlass Pharma™ Completes Enrollment in Phase I/II Study of its Promising Long-Term Drug Delivery Platform for Glaucoma and Ocular Hypertension

ALISO VIEJO, Calif., November 19, 2024 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately-held ophthalmic biotechnology company, today announced completion of enrollment in its Phase I/II, randomized, multi-center, controlled clinical trial (NCT06120842) evaluating SpyGlass’ Drug Delivery Platform in patients with glaucoma or ocular hypertension. The SpyGlass platform is designed to deliver multiple years of bimatoprost to lower intraocular pressure (IOP) and is implanted during routine cataract surgery. (View full press release)

Spyglass Pharma Logo - Long - Black_edited.png

Technology

Tel: 949-284-6904

About

27061 Aliso Creek Rd, Suite 100
Aliso Viejo, CA 92656

Investors

CONTACT US

SUBSCRIBE

Sign up to receive SpyGlass Pharma™ news and updates.

Thanks for submitting!

© 2024 SpyGlass Pharma™. All Rights Reserved.

Follow us on LinkedIn

  • LinkedIn
bottom of page